Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer
Section snippets
Conflict of interest
None
References (11)
- et al.
ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition
Cell Rep.
(2017) - et al.
Targeting BRAF-mutant Non-small cell lung cancer: from molecular profiling to rationally designed therapy
Oncologist
(2017) - et al.
Clinical impact of extensive molecular profiling in advanced cancer patients
J. Hematol. Oncol.
(2017) - et al.
CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications
Ann. Oncol.
(2018) - et al.
Cancer chromosomal instability: therapeutic and diagnostic challenges
EMBO Rep.
(2012)
There are more references available in the full text version of this article.
Cited by (2)
BRAF: Novel Therapies for an Emerging Target
2019, Current Cancer Research
© 2018 Elsevier B.V. All rights reserved.